Daclatasvir and sofosbuvir are drugs that directly suppress the hepatitis C virus (HCV). They are often used together to treat different genotypes of the virus.

Daclatasvir blocks the NS5A protein, which is necessary for the virus to reproduce. Sofosbuvir* interferes with the work of the enzyme that copies viral RNA.

This combination effectively combats all HCV genotypes (1-6) and reduces the risk of resistance to treatment.

When they appoint

Daclatasvir and sofosbuvir are used in different cases:

• Acute hepatitis C (any genotypes).
• Chronic hepatitis C (all genotypes).
• Combination of hepatitis C and HIV infection.
• Cirrhosis of the liver.
• Re-infection after liver transplantation.
• Complications of hepatitis related to the immune system.

Treatment should be prescribed and supervised by a doctor specializing in hepatitis C.

Who is not allowed to take

It is not recommended to use daclatasvir with sofosbuvir:

• Allergic to daclatasvir.
• If medications that enhance the activity of CYP3A4 are taken (this reduces the effectiveness of treatment).
• Pregnant or lactating women.
• Patients under 18 years of age (no studies have been conducted).

Daclatasvir and sofosbuvir should not be combined with amiodarone, as this can cause a dangerous slowing of the heartbeat.

How to take

The course of treatment depends on the genotype of the virus and the condition of the liver.:

• For genotypes 1, 2, 3 and 4 (without cirrhosis): 12 weeks. If the patient has already tried other drugs, the course is also 12 weeks.
• For cirrhosis (grades A or B on the Child-Pugh scale): 12 weeks for genotypes 1, 2 and 3. For genotype 3, the course can be extended to 24 weeks.
• For patients with Child-Pugh class C cirrhosis or ribavirin intolerance: 24 weeks without ribavirin.

Possible side effects

Common side effects include:

• Fatigue.
• Headache.
• Nausea.